Prognostic Value of Ki-67 in Breast Cancer
Author Information
Author(s): M. Railo, S. Nordling, K. von Boguslawsky, M. Leivonen, L. Kyllnen, K. von Smitten
Primary Institution: Helsinki University Central Hospital
Hypothesis
The study evaluates the prognostic value of Ki-67 immunohistochemical labelling in primary operable breast cancer.
Conclusion
Ki-67 labelling is a useful prognostic indicator for disease-free survival in breast cancer patients.
Supporting Evidence
- Ki-67 positive patients had shorter disease-free survival compared to Ki-67 negative patients.
- Combining Ki-67 expression with ER receptors identified subgroups with different disease-free survival.
- Independent prognostic factors included ER, Ki-67, tumour size, and nodal status.
Takeaway
This study found that a special test called Ki-67 can help doctors understand how likely it is for breast cancer to come back after treatment.
Methodology
The study involved 327 patients with primary breast carcinoma, evaluating Ki-67 and ER status and their correlation with disease-free survival using statistical models.
Limitations
The follow-up period was relatively short, with a maximum of 4 years.
Participant Demographics
The mean age of participants was 57 years, with a range from 28 to 86 years.
Statistical Information
P-Value
<0.0001 for ER, <0.02 for Ki-67, <0.0001 for tumour size, <0.006 for nodal status
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website